CLDN9

Xencor Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLDN3, Ovarian cancer, CD28, Telephone, STEAP1, OMERS, CLDN4, Sale, Vir, ESMO, Amgen, Cytokine, Gilead Sciences, Antibody, Part, Safety, Cancer, Investment, Patient, Congress, G&A, Prostate cancer, CTA, ENPP3, CLDN6, Liver disease, Genentech, European Society for Medical Oncology, CLDN9, Tafasitamab, IND, CD3, Colorectal cancer, R, Environment, Ravulizumab, Lung cancer, PARP, Vaccine, Pharmaceutical industry, Medical imaging, Rare-earth element, Cryptocurrency, Omeros, Janssen, MorphoSys, Alexion, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.
  • Total revenue for the third quarter ended September 30, 2023 was $59.2 million, compared to $27.3 million for the same period in 2022.
  • Decreased net loss in the third quarter of 2023 compared to 2022 is primarily due to additional income earned.
  • ET (1:30 p.m. PT) to discuss the third quarter 2023 financial results and provide a corporate update.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Retrieved on: 
Wednesday, January 4, 2023
Cancer, Standard of care, Clinical trial, Partnership, Death, Lung, Bi-specific T-cell engager, Fulvestrant, CLDN9, Female, Breast cancer, Breast, Toxicity, Metastasis, OATH, PFS, Growth, Patient, Endometrial cancer, Uterus, PR, FDA, IND, SMILE, Progesterone, Taxane, Survival, CLDN6, Context, Birth control, Pharmaceutical industry

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today provided 2022 year-end updates and corporate guidance for 2023.

Key Points: 
  • "I am proud of the substantial progress the Context team made in 2022.
  • "In 2023, we will continue to advance ONA-XR across the endometrial (OATH) and breast (SMILE and ELONA) cancer clinical trials.
  • During Q4 2022, Context presented preclinical data introducing CTIM-76 as a differentiated, potent, and selective CLDN6-directed immunotherapy.
  • IND-enabling studies are scheduled for 2023 with an IND filing to support human clinical trials expected in Q1 2024.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Antibody, Safety, CDH17, Metastasis, CAR, Tight junction proteins, CLDN6, Drug discovery, Ligand, Industry, Trial of the century, Embryonic development, B-cell maturation antigen, Population, Glycoprotein, EC, BCMA, Cancer, Cell adhesion, B cell, Tissue, ROR1, Testicle, Receptor, Cadherin, Nephron, Probability, Patient, Cell, CD138, Skin, Competitive landscape, GPRC5D, Immunotherapy, Perspiration, Protein, Multiple myeloma, Organogenesis, CLDN9, Human, Adult, Dietary supplement, Vaccine, Retail, Medical imaging, Healthcare, Pharmaceutical industry, Risk management, Sales

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Health, Pharmaceutical, Target, Antibody, Cancer, CAR, Cell, Drug discovery, CLDN6, CLDN9, Protein, Tissue, Adult, Tight junction proteins, Vaccine, Medical imaging, Pharmaceutical industry

The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • Despite the technical challenge, novel cellular and humoral CLDN6-targeted drug modalities have emerged and the first product candidates entered clinical development.
  • The facts that preliminary clinical experience shows high anti-tumor activity of the first drug candidate and that the competitive field still is limited, make claudin 6 an exceptionally attractive target for drug discovery and development.

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Syngenic, Private Securities Litigation Reform Act, Company, PDX, Therapy, Cell, Cancer, Progesterone, Lung, Ovary, Forward-looking statement, Immunotherapy, CLDN6, Growth, PR, IND, Breast, AACR, American Association, AURKA, ER, Letrozole, CD3, SVP, 2021 Essex County Council election, American Association for Cancer Research, Association, Endometrial cancer, Safety, Fulvestrant, Intention, Oncofetal antigen, KLF4, Nasdaq, U.S. Securities and Exchange Commission, GLOBE, Immunomodulation, Testicular cancer, CLDN9, Anastrozole, Context, Vaccine, Internet service provider, Pharmaceutical industry, P4, Monoclonal antibody

PHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • With respect to our CLDN6xCD3 bispecific program, we are encouraged by preclinical findings which highlight the programs selectivity and potency.
  • ET, Context will host a webinar with its management team and AACR presenters, to discuss the results from these presentations.
  • Following the formal presentation, the Context team, along with AACR presenters, will be available for questions.